JP2021063090A5 - - Google Patents

Download PDF

Info

Publication number
JP2021063090A5
JP2021063090A5 JP2020209896A JP2020209896A JP2021063090A5 JP 2021063090 A5 JP2021063090 A5 JP 2021063090A5 JP 2020209896 A JP2020209896 A JP 2020209896A JP 2020209896 A JP2020209896 A JP 2020209896A JP 2021063090 A5 JP2021063090 A5 JP 2021063090A5
Authority
JP
Japan
Prior art keywords
seq
nos
antigen
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020209896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021063090A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021063090A publication Critical patent/JP2021063090A/ja
Publication of JP2021063090A5 publication Critical patent/JP2021063090A5/ja
Pending legal-status Critical Current

Links

JP2020209896A 2014-06-19 2020-12-18 多細菌性感染の治療 Pending JP2021063090A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462014506P 2014-06-19 2014-06-19
US62/014,506 2014-06-19
US201562140849P 2015-03-31 2015-03-31
US62/140,849 2015-03-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016573926A Division JP6845016B2 (ja) 2014-06-19 2015-06-19 多細菌性感染の治療

Publications (2)

Publication Number Publication Date
JP2021063090A JP2021063090A (ja) 2021-04-22
JP2021063090A5 true JP2021063090A5 (https=) 2021-06-10

Family

ID=54936121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573926A Active JP6845016B2 (ja) 2014-06-19 2015-06-19 多細菌性感染の治療
JP2020209896A Pending JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016573926A Active JP6845016B2 (ja) 2014-06-19 2015-06-19 多細菌性感染の治療

Country Status (11)

Country Link
US (1) US11168132B2 (https=)
EP (1) EP3157565B1 (https=)
JP (2) JP6845016B2 (https=)
KR (1) KR102549870B1 (https=)
CN (1) CN106456767B (https=)
AU (1) AU2015276938B2 (https=)
CA (1) CA2952278A1 (https=)
ES (1) ES2983252T3 (https=)
SG (2) SG11201609652RA (https=)
TW (1) TWI719938B (https=)
WO (1) WO2015196011A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
WO2017095744A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
SG11201809778TA (en) 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン,エルエルシー S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体
TWI895248B (zh) 2018-10-09 2025-09-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
EP3983015A1 (en) * 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2025117765A1 (en) * 2023-12-01 2025-06-05 University Of Washington Protective monoclonal antibodies to pseudomonas aeruginosa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131457A1 (en) 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
WO2011087799A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
HRP20201370T1 (hr) * 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
BR112015010125A2 (pt) 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Similar Documents

Publication Publication Date Title
JP2021063090A5 (https=)
JP2017519768A5 (https=)
US20250243262A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
JP6845016B2 (ja) 多細菌性感染の治療
JP2016507470A5 (https=)
CN103906535B (zh) 与葡萄球菌蛋白a的抗体相关的组合物和方法
RU2015121624A (ru) Антитела к поверхностным детерминантам s. aureus
JP6192294B2 (ja) グラム陽性菌特異的結合化合物
JP2020037555A5 (https=)
JP2014508748A5 (https=)
JP2022512647A5 (https=)
JP2015514110A5 (https=)
JP2009225799A5 (https=)
JP2008501317A5 (https=)
JP2015504421A5 (https=)
JP2013515079A5 (https=)
JP2025032102A5 (https=)
JP2023089191A5 (https=)
JP2022536469A5 (https=)
RU2016116949A (ru) Анти-лпс о11-антитело
JP2018529661A5 (https=)
RU2015121617A (ru) Способы лечения заболеваний, ассоциированных с s. aureus
JP2006514636A5 (https=)
JP2022516351A5 (https=)
JP2022512904A5 (https=)